Anne L Carlton1, Anuradha Illendula2, Yan Gao2, Danielle C Llaneza3, Adam Boulton2, Anant Shah4, Roger A Rajewski5, Charles N Landen3, David Wotton4, John H Bushweller6. 1. Department of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, VA 22908, USA; Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, VA 22908, USA. 2. Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, VA 22908, USA. 3. Department of Obstetrics and Gynecology, University of Virginia, Charlottesville, VA 22908, USA. 4. Department of Biochemistry and Molecular Genetics and Center for Cell Signaling, University of Virginia, Charlottesville, VA 22908, USA. 5. Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS 66045, USA. 6. Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, VA 22908, USA. Electronic address: jhb4v@virginia.edu.
Abstract
OBJECTIVE: Ovarian cancer survival and treatment have improved minimally in the past 20years. Novel treatment strategies are needed to combat this disease. This study investigates the effects of chemical inhibition of the CBFβ/RUNX protein-protein interaction on ovarian cancer cell lines. METHODS: Ovarian cancer cell lines were treated with CBFβ/RUNX inhibitors, and the effects on proliferation, DNA replication, wound healing, and anchorage-independent growth were measured. RNA-Seq was performed on compound-treated cells to identify differentially expressed genes. Genes altered by compound treatment were targeted with siRNAs, and effects on DNA replication and wound healing were measured. RESULTS: Chemical inhibition of the CBFβ/RUNX interaction decreases ovarian cancer cell proliferation. Inhibitor treatment leads to an S-phase cell cycle delay, as indicated by an increased percentage of cells in S-phase, and a decreased DNA replication rate. Inhibitor treatment also reduces wound healing and anchorage-independent growth. RNA-Seq on compound-treated cells revealed changes in a small number of genes related to proliferation and epithelial-to-mesenchymal transition. siRNA-mediated knockdown of INHBA and MMP1 - two genes whose expression decreases with compound treatment - slowed DNA replication and impaired wound healing. CONCLUSIONS: Chemical inhibition of the CBFβ/RUNX interaction is a viable strategy for the treatment of ovarian cancer.
OBJECTIVE:Ovarian cancer survival and treatment have improved minimally in the past 20years. Novel treatment strategies are needed to combat this disease. This study investigates the effects of chemical inhibition of the CBFβ/RUNX protein-protein interaction on ovarian cancer cell lines. METHODS:Ovarian cancer cell lines were treated with CBFβ/RUNX inhibitors, and the effects on proliferation, DNA replication, wound healing, and anchorage-independent growth were measured. RNA-Seq was performed on compound-treated cells to identify differentially expressed genes. Genes altered by compound treatment were targeted with siRNAs, and effects on DNA replication and wound healing were measured. RESULTS: Chemical inhibition of the CBFβ/RUNX interaction decreases ovarian cancer cell proliferation. Inhibitor treatment leads to an S-phase cell cycle delay, as indicated by an increased percentage of cells in S-phase, and a decreased DNA replication rate. Inhibitor treatment also reduces wound healing and anchorage-independent growth. RNA-Seq on compound-treated cells revealed changes in a small number of genes related to proliferation and epithelial-to-mesenchymal transition. siRNA-mediated knockdown of INHBA and MMP1 - two genes whose expression decreases with compound treatment - slowed DNA replication and impaired wound healing. CONCLUSIONS: Chemical inhibition of the CBFβ/RUNX interaction is a viable strategy for the treatment of ovarian cancer.
Authors: T Komori; H Yagi; S Nomura; A Yamaguchi; K Sasaki; K Deguchi; Y Shimizu; R T Bronson; Y H Gao; M Inada; M Sato; R Okamoto; Y Kitamura; S Yoshiki; T Kishimoto Journal: Cell Date: 1997-05-30 Impact factor: 41.582
Authors: Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov Journal: Proc Natl Acad Sci U S A Date: 2005-09-30 Impact factor: 11.205
Authors: Adam H Greer; Thomas Yong; Katie Fennell; Yara W Moustafa; Marcie Fowler; Floyd Galiano; Shu-Wing Ng; Ross S Berkowitz; James Cardelli; Shari Meyers; J Nathan Davis Journal: J Cell Physiol Date: 2013-12 Impact factor: 6.384
Authors: Anuradha Illendula; Jane Gilmour; Jolanta Grembecka; Venkata Sesha Srimath Tirumala; Adam Boulton; Aravinda Kuntimaddi; Charles Schmidt; Lixin Wang; John A Pulikkan; Hongliang Zong; Mahmut Parlak; Cem Kuscu; Anna Pickin; Yunpeng Zhou; Yan Gao; Lauren Mishra; Mazhar Adli; Lucio H Castilla; Roger A Rajewski; Kevin A Janes; Monica L Guzman; Constanze Bonifer; John H Bushweller Journal: EBioMedicine Date: 2016-04-29 Impact factor: 8.143
Authors: Filip Matthijssens; Nitesh D Sharma; Monique Nysus; Christian K Nickl; Huining Kang; Dominique R Perez; Beatrice Lintermans; Wouter Van Loocke; Juliette Roels; Sofie Peirs; Lisa Demoen; Tim Pieters; Lindy Reunes; Tim Lammens; Barbara De Moerloose; Filip Van Nieuwerburgh; Dieter L Deforce; Laurence C Cheung; Rishi S Kotecha; Martijn Dp Risseeuw; Serge Van Calenbergh; Takeshi Takarada; Yukio Yoneda; Frederik W van Delft; Richard B Lock; Seth D Merkley; Alexandre Chigaev; Larry A Sklar; Charles G Mullighan; Mignon L Loh; Stuart S Winter; Stephen P Hunger; Steven Goossens; Eliseo F Castillo; Wojciech Ornatowski; Pieter Van Vlierberghe; Ksenia Matlawska-Wasowska Journal: J Clin Invest Date: 2021-03-15 Impact factor: 14.808
Authors: Fernando Alegre; Amanda R Ormonde; Dayn R Godinez; Anuradha Illendula; John H Bushweller; Luke A Wittenburg Journal: Vet Comp Oncol Date: 2019-08-22 Impact factor: 2.613
Authors: Joshua T Rose; Eliana Moskovitz; Joseph R Boyd; Jonathan A Gordon; Nicole A Bouffard; Andrew J Fritz; Anuradha Illendula; John H Bushweller; Jane B Lian; Janet L Stein; Sayyed K Zaidi; Gary S Stein Journal: Oncotarget Date: 2020-06-30